Aberrant Expression of CD8 in B-Cell Non-Hodgkin Lymphoma

Carulli, Giovanni; Stacchini, Alessandra; Marini, Alessandra; Ciriello, Maria Matilde; Zucca, Alessandra; Cannizzo, Elisa; Aliberti, Sabrina; Demurtas, Anna; Novero, Domenico; Calcagno, Lara; Callegari, Tiziana; Petrini, Mario

doi:10.1309/ajcpncohs92arwrq

Cited by 37 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that CD2 and CD7 expression is relatively common, in agreement with several reports on B-cell NHL (B-NHL), e.g. studies on the expression of CD7 (5%) and CD2 (2%) reported by Inaba et al [20,21], CD2 and CD8 by Kaleem et al [22], CD2 (38%) and CD7 (19%) by Schmidt et al [23], and CD8 (1.18%) by Carulli et al [24]. …”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Suzuki¹,

Yoshida²,

Wang³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

Introduction: Aberrant expression of T-cell markers is occasionally observed in B-cell lymphomas. We conducted a retrospective study to establish its incidence and to determine its relationship with clinical features of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: We reviewed DLBCL patients diagnosed between January 2002 and April 2009. Patients fulfilled the following criteria: (1) age >18 years, (2) HIV negative, (3) B-cell lymphoma confirmed by restricted expression of surface immunoglobulin light chains by flow cytometry (FCM). Aberrant T-cell marker expression (ATCME) was defined as positivity for CD2, CD3, CD4, CD7, and/or CD8 on DLBCL cells by FCM. Phenotyping was also performed by immunohistochemistry (IHC). Patients were grouped according to positive or negative ATCME and their clinical features including survival were compared. Results: Of 150 patients, 11 (7.3%) showed ATCME; CD2 and CD7 were most often expressed. ATCME was less often detected and the signal was weaker using IHC. There were no statistically significant differences in clinical features between the two groups. Conclusions: FCM may be useful to detect ATCME in a small amount of lymphoma cells. The mechanism responsible for ATCME, and whether it contributes in any way to the pathogenesis of B-cell neoplastic transformation, requires clarification.

show abstract

Section: Discussionsupporting

confidence: 89%

“…In the literature, CD2 or CD7 expression is reported to be associated with extranodal involvement in B-NHL at diagnosis [20]. Carulli et al [24] estimated the frequency of CD8-positive B-NHL to be 1.89%, similar to our finding (1.7%). They suggested that such B-NHLs are characterized by a more favorable outcome.…”

Section: Discussionsupporting

confidence: 89%

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Suzuki¹,

Yoshida²,

Wang³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…The most frequently reported cases have been CD8 + CLLs, accounting for 0.5–3% of the total CLLs [6, 7, 10–13]. This frequency is consistent with the present finding that CD8 was the most frequently expressed marker among T-cell markers other than CD5, even though no CD8 + CLLs were found (0/13).…”

Section: Discussionsupporting

confidence: 90%

“…Studies evaluating expression of T-cell marker other than CD5 with a large sample size have been reported, but these results did not represent the demography of non-Hodgkin lymphoma subtypes. Carulli et al [13] reported eight patients with non-Hodgkin lymphoma showing aberrant expression of CD8 in 951 bone marrow samples, but that study was sharply biased in patient selection toward lymphomas with bone marrow invasion, such as CLLs/SLLs. In other studies [13, 17, 18] using more than 100 cases, variable histological classification, not the current WHO criteria, was applied, which does not represent the accurate distribution of non-Hodgkin lymphoma.…”

Section: Discussionmentioning

confidence: 99%

“…Although B-cell lymphomas with T-cell markers other than CD5, such as CD8 + CLL [5–13] or CD2/CD3/CD4/CD7/CD8 + large B-cell lymphoma [13–31] have been reported (Table 1), data regarding their frequency, histopathological distribution, and clinical features are rarely available, because the number of identified cases in each report is small. This rarity may partly be attributed to the differences in the immunophenotypic procedures used.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases ofde novodiffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

et al. 2017

View full text Add to dashboard Cite

Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5%) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15% (31/225) and 10% (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses.

show abstract

References

2021

Flow Cytometry of Hematological Malignancies

View full text Add to dashboard Cite

Aberrant Expression of CD8 in B-Cell Non-Hodgkin Lymphoma

Cited by 37 publications

References 23 publications

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases ofde novodiffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

References

Contact Info

Product

Resources

About